🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 6 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 29/07/2011 | 49,89 | 52,63 | 48,45 | 51,86 | +8,09% | 8,38% | 4.954.800 |
| 28/07/2011 | 47,92 | 49,80 | 47,51 | 47,98 | +0,13% | 4,78% | 1.983.700 |
| 27/07/2011 | 49,22 | 49,35 | 47,15 | 47,92 | -3,29% | 4,47% | 1.454.500 |
| 26/07/2011 | 49,47 | 49,87 | 48,12 | 49,55 | +0,20% | 3,54% | 1.336.400 |
| 25/07/2011 | 50,48 | 50,79 | 49,34 | 49,45 | -3,00% | 2,87% | 1.108.200 |
| 22/07/2011 | 51,27 | 51,51 | 50,63 | 50,98 | -0,37% | 1,72% | 759.800 |
| 21/07/2011 | 50,47 | 51,84 | 50,33 | 51,17 | +1,93% | 2,99% | 1.273.100 |
| 20/07/2011 | 50,62 | 50,64 | 49,46 | 50,20 | -1,41% | 2,33% | 1.019.800 |
| 19/07/2011 | 49,99 | 51,07 | 49,90 | 50,92 | +2,72% | 2,34% | 1.007.800 |
| 18/07/2011 | 50,07 | 50,83 | 49,33 | 49,57 | -2,19% | 3,00% | 1.693.700 |
| 15/07/2011 | 50,28 | 51,28 | 50,24 | 50,68 | +0,70% | 2,07% | 1.778.600 |
| 14/07/2011 | 51,00 | 52,44 | 50,18 | 50,33 | -2,25% | 4,43% | 1.640.200 |
| 13/07/2011 | 51,57 | 52,33 | 51,18 | 51,49 | +0,16% | 2,23% | 1.681.400 |
| 12/07/2011 | 50,15 | 51,83 | 50,05 | 51,41 | +2,27% | 3,55% | 1.695.600 |
| 11/07/2011 | 50,22 | 50,86 | 49,77 | 50,27 | -0,79% | 2,17% | 1.099.700 |
| 08/07/2011 | 49,22 | 50,74 | 49,22 | 50,67 | +1,08% | 3,09% | 969.100 |
| 07/07/2011 | 50,21 | 50,33 | 49,05 | 50,13 | -0,08% | 2,55% | 2.628.000 |
| 06/07/2011 | 51,89 | 52,00 | 49,82 | 50,17 | -3,87% | 4,20% | 2.573.500 |
| 05/07/2011 | 51,84 | 52,22 | 51,62 | 52,19 | +0,95% | 1,16% | 1.180.800 |
| 01/07/2011 | 51,49 | 51,92 | 51,08 | 51,70 | -0,56% | 1,63% | 1.484.500 |
| 30/06/2011 | 52,39 | 52,78 | 51,71 | 51,99 | -0,54% | 2,04% | 1.845.600 |
| 29/06/2011 | 50,81 | 52,27 | 50,23 | 52,27 | +3,04% | 4,01% | 2.433.900 |
| 28/06/2011 | 48,97 | 51,48 | 48,71 | 50,73 | +4,13% | 5,66% | 2.766.000 |
| 27/06/2011 | 48,42 | 48,74 | 48,06 | 48,72 | +0,27% | 1,40% | 1.610.000 |
| 24/06/2011 | 47,99 | 48,79 | 47,50 | 48,59 | +1,19% | 2,69% | 2.964.900 |
| 23/06/2011 | 46,37 | 48,15 | 45,89 | 48,02 | +1,72% | 4,87% | 2.696.900 |
| 22/06/2011 | 45,57 | 47,89 | 45,50 | 47,21 | +2,97% | 5,24% | 2.765.500 |
| 21/06/2011 | 45,22 | 45,97 | 44,68 | 45,85 | +1,53% | 2,85% | 1.469.000 |
| 20/06/2011 | 44,78 | 46,25 | 44,58 | 45,16 | +0,33% | 3,73% | 2.142.800 |
| 17/06/2011 | 46,20 | 46,38 | 44,57 | 45,01 | -1,27% | 3,92% | 3.131.200 |